• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Adapt Pharma seeks regulatory nod for naloxone nasal spray in Europe

February 21, 2017 By Sarah Faulkner

Adapt Pharma seeks regulatory nod for naloxone nasal spray in EuropeAdapt Pharma said today that it filed a European Marketing Application for its naloxone hydrochloride nasal spray for the treatment of opioid overdose.

The Dublin-based company’s product is a ready-to-use, needle-free device that delivers a single dose of naloxone in an 0.1 mL nasal spray and does not require assembly prior to use, according to Adapt Pharma.

The company’s nasal sprays are comprised of concentrated naloxone that provides emergency treatment for opioid overdose, including prescription opioid painkiller-related overdose, fentayl, carfentanil, and heroin-related overdose.

Healthcare practitioners have used injectable naloxone to treat opioid overdose patients for more than 40 years. In 2016, Health Canada approved Adapt Pharma’s Narcan naloxone nasal spray – 1 year after the FDA approved the product in the U.S.

The company’s products are the 1st and only nasal formulation of naloxone available in the U.S., Canada and Europe, according to Adapt Pharma, and its nasal sprays are the most frequently prescribed formulation of naloxone in U.S.-based pharmacies.

A 29-patient pharmacokinetic study demonstrated that the naloxone nasal spray achieved naloxone plasma levels greater than those achieved by the instramuscular naloxone injection, Adapt Pharma reported.

In January this year, the FDA approved the 2mg formulation of its Narcan nasal spray for the emergency treatment of opioid overdose.

The 2mg dose is intended for opioid-dependent patients that are at risk for severe withdrawal, but are not at a high risk for continued opioid exposure.

The 4mg nasal spray has been commercially available since February last year, after it was reviewed and approved by the FDA under an expedited pathway.

Filed Under: Featured, Pain Management, Regulatory/Compliance, Wall Street Beat Tagged With: Adapt Pharma

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS